BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
2022年10月12日 - 9:00PM
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
“Company”), a global leader in the advanced noninvasive treatment
of brain disorders, today announced the launch of its nationwide
Sweepstakes - Don’t Miss Another Moment - in conjunction with
Depression Awareness Month. Participants on social media can enter
starting Friday, Oct. 14 and continue throughout the month of
October for a chance to win a $2,000 Airbnb gift card.
The focus of the campaign is to showcase BrainsWay’s first-ever
commercial that encourages people living with mental health
disorders to find help so they don’t miss another moment of their
lives. Many times those with a mental health condition miss out on
life’s most precious moments due to depression,
obsessive-compulsive disorder (OCD), and more.
“It is our mission at BrainsWay to boldly advance neuroscience
to improve health and transform lives. We want to create a world
where mental health is within reach for all,” said BrainsWay
President and CEO Christopher von Jako, Ph.D. “Many people living
with a mental health condition like depression often miss out on
life’s most precious moments. We hope that this year’s Sweepstakes
prize allows someone to create special moments and memories with
their loved ones through travel.”
To enter the Sweepstakes, participants must
follow or like one of BrainsWay’s
social channels (Facebook, LinkedIn, Instagram), and
share the Don’t Miss Another Moment commercial
using the hashtag #DontMissAnotherMoment to
qualify.
The Don’t Miss Another Moment Sweepstakes demonstrates
BrainsWay’s commitment to raising awareness and education around
mental health, in observance of Depression Awareness Month. It
allows social media users to learn from those living with mental
health conditions and helps alleviate the stigma of seeking help.
No one should have to miss out on cherished life moments due to
mental illness.
About BrainsWayBrainsWay is a
global leader in advanced noninvasive neurostimulation treatments
for mental health disorders. The Company is boldly advancing
neuroscience with its proprietary Deep Transcranial Magnetic
Stimulation (Deep TMS™) platform technology to improve health and
transform lives. BrainsWay is the first and only TMS company to
obtain three FDA-cleared indications backed by pivotal studies
demonstrating clinically proven efficacy. Current indications
include major depressive disorder (including reduction of anxiety
symptoms, commonly referred to as anxious depression),
obsessive-compulsive disorder, and smoking addiction. The Company
is dedicated to leading through superior science and building on
its unparalleled body of clinical evidence. Additional clinical
trials of Deep TMS in various psychiatric, neurological, and
addiction disorders are underway. Founded in 2003, with offices in
Burlington, MA and Jerusalem, Israel, BrainsWay is committed to
increasing global awareness of and broad access to Deep TMS. For
the latest news and information about BrainsWay, please visit
www.brainsway.com.
Forward Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements may be preceded by the words “intends,” “may,”
“will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. These forward-looking statements and their implications are
based on the current expectations of the management of the Company
only and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. Moreover, the pilot
data presented herein, including outcomes/results, patient safety
information and adverse event data, remain subject to further
analysis and may be subject to further modification. Certain
results as expressed herein may be subject to further analysis,
modification and/or statistical penalties. In addition, historical
results or conclusions from scientific research and clinical
studies do not guarantee that future results would suggest similar
conclusions or that historical results referred to herein would be
interpreted similarly in light of additional research or otherwise.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: inadequacy of financial resources to meet future
capital requirements; changes in technology and market
requirements; delays or obstacles in launching and/or successfully
completing planned studies and clinical trials; failure to obtain
approvals by regulatory agencies on the Company’s anticipated
timeframe, or at all; inability to retain or attract key employees
whose knowledge is essential to the development of Deep TMS
products; unforeseen difficulties with Deep TMS products and
processes, and/or inability to develop necessary enhancements;
unexpected costs related to Deep TMS products; failure to obtain
and maintain adequate protection of the Company’s intellectual
property, including intellectual property licensed to the Company;
the potential for product liability; changes in legislation and
applicable rules and regulations; unfavorable market perception and
acceptance of Deep TMS technology; inadequate or delays in
reimbursement from third-party payers, including insurance
companies and Medicare; inability to commercialize Deep TMS,
including internationally, by the Company or through third-party
distributors; product development by competitors; inability to
timely develop and introduce new technologies, products and
applications; continuation and/or exacerbation of the global supply
chain crisis and its impact on the Company’s ability to source
components, meet customer demand, fill orders, maintain pricing
levels and support the Company’s service needs; and the effect of
the global COVID-19 health pandemic on our business and continued
uncertainty and market impact relating thereto.
Any forward-looking statement in this press
release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in the Company’s filings with the U.S.
Securities and Exchange Commission, including the Company’s Annual
Report on Form 20-F. Investors and security holders are urged to
read these documents free of charge on the SEC’s web site at
http://www.sec.gov.
Media Contact: Meghan Seale Laska (610)
212-0125 Meghan.Laska@BrainsWay.com
Brainsway (NASDAQ:BWAY)
過去 株価チャート
から 9 2024 まで 10 2024
Brainsway (NASDAQ:BWAY)
過去 株価チャート
から 10 2023 まで 10 2024